Pacira BioSciences (PCRX) Short term Debt (2010 - 2025)

Pacira BioSciences' Short term Debt history runs 14 years deep, the most recent figure standing at $202.4 million for Q2 2025.

• On a quarterly basis, Short term Debt changed N/A year-over-year to $202.4 million in Q2 2025; TTM through Jun 2025 was $202.4 million, a N/A change from a year earlier, with the FY2024 full-year figure at $201.8 million, up 2235.1% from the prior year.
• Short term Debt was little changed at $202.4 million in Q2 2025 per PCRX's latest filing, from $202.1 million in the prior quarter.
• Across five years, Short term Debt topped out at $350.5 million in Q4 2021 and bottomed at $8.6 million in Q2 2023.
• The 5-year median for Short term Debt is $151.6 million (2021), against an average of $117.1 million.
• Across the five-year window, Short term Debt slumped 90.4% in 2022 and surged 2238.69% in 2025, its largest moves.
• Year by year, Short term Debt stood at $350.5 million in 2021, then slumped by 90.4% to $33.6 million in 2022, then tumbled by 74.32% to $8.6 million in 2023, then soared by 2235.1% to $201.8 million in 2024, then grew by 0.31% to $202.4 million in 2025.
• Per Business Quant, the three latest PCRX Short term Debt figures stand at $202.4 million (Q2 2025), $202.1 million (Q1 2025), and $201.8 million (Q4 2024).